림프절전이가 없는 폐경 후 유방암의 호르몬치료제로서 Tamoxifen과 Toremifene의 비교

• Published in: Annals of surgical treatment and research Vol. 63; no. 4; pp. 283 - 286
• Main Authors: 한세환(Sehwan Han), 양근호(Keun Ho Yang), 배병노(Byung Noe Bae), 김기환(Ki Hwan Kim), 김홍주(Hong Joo Kim), 김영덕(Young Duck Kim), 김홍용(Hong Yong Kim)
• Format: Journal Article
• Language: Korean
• Published: 대한외과학회 01.10.2002
• Subjects: 일반외과학
• ISSN: 2288-6575; 2288-6796

Purpose: To evaluate the differences in therapeutic efficacy and toxicity profiles between adjuvant toremifene and tamoxifene in postmenopausal breast cancer patients. Methods: Toremifene 40 mg (n=115) and tamoxifen 20 mg (n =116) were administered daily for more than 2 years after curative surgery for lymph node-negative breast cancer. Toxicity profiles were compared between the two groups and the patient survival rate was also analyzed. Results: Sweating and hot flashes were the most common symptoms in the two groups (toremifene vs. tamoxifen= 47.8% vs. 49.1%). Increase of vaginal discharge (39.1% vs. 36.2%) and weight gain (21.7% vs. 24.1%) were the next following adverse effects. There was no significant difference in adverse effect between the two groups. During the median follow-up period of 25 months (range: 9～38 months), five (4.3%) and four (3.3%) patients treated by toremifene and tamoxifen, respectively, had recurrent disease. Conclusion: The clinical outcome and adverse effect profiles of toremifene were similar to those of tamoxifen. Toremifene at 40 mg/day seems to be as safe and effective as tamoxifen at 20 mg/day in the treatment of postmenopausal, node-negative, breast cancer. However, a longer follow-up study is needed to verify this. (J Korean Surg Soc 2002; 63:283-286) KCI Citation Count: 2